Gordon Carl L bought 20,700 shares of Electra Therapeutics, Inc. at $8.45 for $175k on Nov 10, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director
DIR
Filed Nov 10, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$174,915Shares × reported price
Shares traded
20,700Common Stock
Price per share
$8.45Reported price. Read footnotes for ranges.
% of reported position traded
0.4%This security and ownership context
Holdings after
5,255,278Indirect · See footnotes
Trade date
Nov 10, 2026Buy
Filed
Nov 10, 2026, 8:14 PM ET1-day reporting delay
Accession
0000947871-26-001011Code P · Transaction 397778
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 5,234,578 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 6, 2026Buy9,816$7.85$77,055.60Trade 397774
Nov 6, 2026Buy39,600$7.85$310,860Trade 397775
Nov 9, 2026Buy4,000$8.24$32,960Trade 397776
Nov 9, 2026Buy16,000$8.24$131,840Trade 397777
Nov 10, 2026Buy2,000$8.45$16,900Trade 397779
6 transaction rows in this filing. Joint filers share the same rows.

ETRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ETRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 18, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +13%1w ago +9%1d ago +2.9%
Returns since7d30d90d180d1y

Footnotes in full

F1: These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII. F2: These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. F3: Each of the Reporting Person, OrbiMed Advisors, GP VII and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.